Community hub
0 subscribers7 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to EB-002.
Nothing was collected or created yet.
EB-002
EB-002
View on Wikipediafrom Wikipedia
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | EB002; EB-373; EB373; Synthetic psilocin prodrug |
| Routes of administration | Oral[1] |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders.[1][2][3][4][5] It is taken orally.[1] The drug is under development by Enveric Biosciences.[1][2][3][5] As of November 2024, it is in the preclinical research stage of development.[1][2] In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million.[3] Its exact chemical structure does not yet appear to have been disclosed.[1]
- ^ a b c d e f "Enveric Biosciences". AdisInsight. 22 November 2024. Retrieved 16 February 2025.
- ^ a b c "Delving into the Latest Updates on EB-373 with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
- ^ a b c Jackson A (12 November 2024). "Enveric inks $62M licensing deal for psilocin prodrug". Green Market Report. Retrieved 16 February 2025.
- ^ "Investigational Psilocin Prodrug Gains Patent Protection for Sleep Disorder Applications". Sleep Review. 18 July 2024. Retrieved 16 February 2025.
- ^ a b Carreon M (30 July 2024). "Another Psychedelic Drug Derivative Secures Patent and Awaits FDA Approval". DoubleBlind Mag. Retrieved 15 March 2025.
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||||||
| Tryptamines |
|
|---|---|
| 4-Hydroxytryptamines and esters/ethers |
|
| 5-Hydroxy- and 5-methoxytryptamines |
|
| N-Acetyltryptamines |
|
| α-Alkyltryptamines |
|
| Cyclized tryptamines |
|
| Isotryptamines | |
| Related compounds |
|
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |